2018-19 Section 7-Neoplastic and Inflammatory Diseases of the Head and Neck eBook

Clinical & Experimental Metastasis

Epidemiology, and End Results (SEER) program. Oncologist 8(6):541–552 42. Merrill RM, Hunter BD (2010) Conditional survival among can- cer patients in the United States. Oncologist 15(8):873–882 43. Kerivan L, Reintgen M, Shivers S, Reintgen E, Reintgen DS (2017) Conditional survival in melanoma: meaningful prognostic information for patients and physicians. Presented at the Society of Surgical Oncology Meeting, March. Seattle, Washington 44. Faries MB (2018) Completing the dissection in melanoma: increasing decision precision. Ann Surg Oncol. https​://doi. org/10.1245/s1043​4-017-6330-4 Jan 4. 45. Rossi CR, Mocellin S, Campana LG et al (2018) Prediction of non-sentinel node status in patients with melanoma and posi- tive sentinel node biopsy: an Italian Melanoma Intergroup (IMI) Study. Ann Surg Oncol 25:271–279

38. Balch C, Gershenwald JE, Soong S-J, Thompson J, Byrd D, Cascinelli N, Cochran AJ, Coit D, Eggermont A, Johnson T, Kirkwood J, Leong S, McMasters K, Mihn M, Morton D, Ross M, Sondak V (2010) Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: Comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452–2459 39. Balch CM, Soon SJ, Atkins MB et al (2004) An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54:131–149 40. Reintgen M, Murray L, Akman K, Giuliano R, Loznicki A, Shivers S, Reintgen DS (2013) Evidence for a better nodal stag- ing system for melanoma: The clinical relevance of metastatic disease confined to the sentinel lymph nodes. Ann Surg Oncol 20:668–674 41. Ries LAG, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003) Cancer survival and incidence from the Surveillance,

13

74